Eisai and Biogen Launch LEQEMBI Pen in Japan
Eisai and Biogen said the subcutaneous formulation of LEQEMBI has launched in Japan for patients with early Alzheimer’s disease.
Eisai and Biogen said the subcutaneous formulation of LEQEMBI has launched in Japan for patients with early Alzheimer’s disease.